Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1992 1
1993 1
1998 1
2001 2
2008 2
2009 2
2011 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
[Penis fracture].
Schrama J, Skjetne O, Vada K. Schrama J, et al. Among authors: vada k. Tidsskr Nor Laegeforen. 1998 May 20;118(13):2017-8. Tidsskr Nor Laegeforen. 1998. PMID: 9656786 Norwegian.
[Perinephritic abscess].
Samdal F, Vada K, Loe B, Mjølnerød OK, Lundmo PI. Samdal F, et al. Among authors: vada k. Tidsskr Nor Laegeforen. 1990 Jun 10;110(15):1952-3. Tidsskr Nor Laegeforen. 1990. PMID: 2194322 Norwegian.
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Widmark A, et al. Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Lancet. 2009. PMID: 19091394 Free article. Clinical Trial.
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fosså S, Widmark A; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Fransson P, et al. Lancet Oncol. 2009 Apr;10(4):370-80. doi: 10.1016/S1470-2045(09)70027-0. Epub 2009 Mar 13. Lancet Oncol. 2009. PMID: 19286422 Clinical Trial.
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP. Hedlund PO, et al. Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31. Scand J Urol Nephrol. 2011. PMID: 21627403 Clinical Trial.
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group. Hedlund PO, et al. Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274. Scand J Urol Nephrol. 2008. PMID: 18432528 Clinical Trial.
Sexual function after transurethral prostatectomy.
Samdal F, Vada K, Lundmo P. Samdal F, et al. Among authors: vada k. Scand J Urol Nephrol. 1993;27(1):27-9. doi: 10.3109/00365599309180410. Scand J Urol Nephrol. 1993. PMID: 7684156
13 results